Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15694MR)

This product GTTS-WQ15694MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15694MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3752MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ3395MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ14553MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ6796MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ12423MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ15859MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ6935MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ6570MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW